Skip to main content Accessibility help
×
Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-24T00:03:03.345Z Has data issue: false hasContentIssue false

1 - History of iron overload disorders

Published online by Cambridge University Press:  01 June 2011

James C. Barton
Affiliation:
University of Alabama, Birmingham
Corwin Q. Edwards
Affiliation:
University of Utah Medical Center
Pradyumna D. Phatak
Affiliation:
University of Rochester Medical Center, New York
Robert S. Britton
Affiliation:
St Louis University, Missouri
Bruce R. Bacon
Affiliation:
St Louis University, Missouri
James C. Barton
Affiliation:
University of Alabama, Birmingham
Corwin Q. Edwards
Affiliation:
University of Utah School of Medicine, Salt Lake City
Pradyumna D. Phatak
Affiliation:
University of Rochester Medical Center, New York
Robert S. Britton
Affiliation:
St Louis University, Missouri
Bruce R. Bacon
Affiliation:
St Louis University, Missouri
Get access

Summary

In 1704 in Berlin, Heinrich Diesbach and Johann Konrad Dippel attempted to manufacture a synthetic red pigment. By accident, Dippel mixed potash, animal oil derived from blood, and iron sulfate. Thereafter, he discovered that he had produced an insoluble, light-fast, dark blue pigment. This color was first used extensively to dye the uniforms of the Prussian army, and became known as “Prussian blue.” Almost 150 years later, physicians and scientists recognized the feasibility of visualizing iron in tissue using a similar staining sequence. After more than 250 years, it became practical to quantify iron in blood and tissue, permitting case finding and screening for hemochromatosis and iron overload. Maneuvers to treat iron overload began in the same era. In the interval 1994–1996, the genetic bases of four different iron disorders (X-linked sideroblastic anemia, aceruloplasminemia, hereditary hyperferritinemia-cataract syndrome, and HFE hemochromatosis) were elucidated. The pace of basic science, clinical, and sociological revelations pertinent to hemochromatosis and iron overload disorders continues to accelerate. This chapter provides an abbreviated chronology of these discoveries.

Iron in tissue

In 1847, Rudolph Virchow reported the occurrence of golden brown granular pigment at sites of hemorrhage and congestion in tissue examined by microscopy. The pigment was soluble in sulfuric acid, yielded a red ash on ignition, and produced a positive Prussian blue reaction. In 1867, Max Perls formulated the first practical acidified ferrocyanide reaction for histologic analysis of iron, and applied the staining reaction to a variety of tissues.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Virchow, R. Die pathologischen Pigmente. Arch Pathol Anat 1847; 1: 379–486.CrossRef
Perls, M. Nachweis von Eisenoxyd in gewissen Pigmenten. Virchow Arch Pathol Anat 1867; 39: 42–8.CrossRef
Scheuer, PJ, Williams, R, Muir, AR. Hepatic pathology in relatives of patients with haemochromatosis. J Pathol Bacteriol 1962; 84: 53–64.CrossRefGoogle ScholarPubMed
Trousseau, A. Glycosurie, diabète sucré. Paris, J.-B. Baillière. 1865; 663–98.Google Scholar
Troisier, M. Diabète sucré. Bull Soc Anat Paris 1871; 16: 231–5.
Recklinghausen, FD. Über hämochromatose. Tagebl Versamml Natur Ärtze Heidelberg 1889; 62: 324–5.
Bezançon, F, Gennes, L, Delarue, J, Oumensky, V. Cirrhose pigmentaire avec infantilisme et insuffisance cardiaque et aplasie endocriniennes multiples. Bull Mém Soc Med Hôp Paris 1932; 48: 967–74.Google Scholar
Gennes, L, Delarue, J, Vericourt, R.Sur un nouveau cas de cirrhose pigmentaire avec infantilisme et myocarde. Le syndrome endocrine-hepato-cardiaque. Bull Mem Soc Méd Hôp Paris 1935; 51: 1228.
Vericourt, RLe syndrome endocrino-hepato-myocardique (sur un aspect des cirrhoses pigmentaires). Paris, 1935.Google Scholar
Strachan, AS.Haemosiderosis and haemochromatosis in South African natives with a comment on the eiology of haemochromatosis. MD Thesis. University of Glasgow, 1929.Google Scholar
Gordeuk, VR, McLaren, CE, MacPhail, AP, Deichsel, G, Bothwell, TH. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan's 1929 thesis revisited. Blood 1996; 87: 3470–6.Google ScholarPubMed
Bacon, BR.Joseph H. Sheldon and hereditary hemochromatosis: historical highlights. J Lab Clin Med 1989; 113: 761–2.Google Scholar
Sheldon, JH. Haemochromatosis. London, Oxford University Press, 1935.Google Scholar
MacDonald, RA. Hemochromatosis and Hemosiderosis. Springfield, Charles C. Thomas, 1964.Google Scholar
Bothwell, TH, Seftel, H, Jacobs, P, Torrance, JD, Baumslag, M.Iron overload in Bantu subjects. Studies on the availability of iron in Bantu beer. Am J Clin Nutr 1964; 14: 47–51.CrossRefGoogle ScholarPubMed
Edwards, CQ, Carroll, M, Bray, P, Cartwright, GE.Hereditary hemochromatosis. Diagnosis in siblings and children. N Engl J Med 1977; 297: 7–13.CrossRefGoogle ScholarPubMed
Cartwright, GE, Edwards, CQ, Kravitz, K, et al. Hereditary hemochromatosis. Phenotypic expression of the disease. N Engl J Med 1979; 301: 175–9.CrossRefGoogle ScholarPubMed
Bassett, ML, Halliday, JW, Powell, LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986; 6: 24–9.CrossRefGoogle ScholarPubMed
Brittenham, GM, Farrell, , Harris, JW, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982; 307: 1671–5.CrossRefGoogle ScholarPubMed
Runge, VM, Clanton, JA, Smith, FW, et al. Nuclear magnetic resonance of iron and copper disease states. Am J Roentgenol 1983; 141: 943–8.CrossRefGoogle ScholarPubMed
Brown, KE, Bacon, BR. Hepatic iron metabolism in hemochromatosis. In: Barton, JC, Edwards, CQ, eds. Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 157–62.CrossRefGoogle Scholar
Adams, PC, Barton, JC. Haemochromatosis. Lancet 2007; 370: 1855–60.CrossRefGoogle ScholarPubMed
Schumacher, HRJ. Hemochromatosis and arthritis. Arth Rheum 1964; 7: 50.CrossRefGoogle ScholarPubMed
Chevrant-Breton, J. Cutaneous manifestations of hemochromatosis. In: Barton, JC, Edwards, CQ, eds. Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 290–6.CrossRefGoogle Scholar
Britton, RS. Mechanisms of iron toxicity. In: Barton, JC, Edwards, CQ, eds. Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 229–38.CrossRefGoogle Scholar
Deugnier, Y, Loréal, O. Iron as a carcinogen. In: Barton, JC, Edwards, CQ, eds. Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 239–49.CrossRefGoogle Scholar
Deugnier, YM, Charalambous, P, Quilleuc, D, et al. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology 1993; 18: 1363–9.Google ScholarPubMed
Deugnier, YM, Guyader, D, Crantock, L, et al. Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 1993; 104: 228–34.CrossRefGoogle ScholarPubMed
Brock, JH. Role of iron in infections and immunity. In: Barton, JC, Edwards, CQ, eds. Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 371–80.CrossRefGoogle Scholar
Bullen, JJ. Bacterial infections in hemochromatosis. In: Barton, JC, Edwards, CQ, eds. Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 381–6.CrossRefGoogle Scholar
Sousa, M, Porto, G, Arosa, FA, et al. T-lymphocyte expression and function in hemochromatosis. In: Barton, JC, Edwards, CQ, eds. Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment. Cambridge, Cambridge University Press. 2000; 396–410.CrossRefGoogle Scholar
Barton, JC, Bertoli, LF, Acton, RT. Common variable immunodeficiency and IgG subclass deficiency in central Alabama hemochromatosis probands homozygous for HFE C282Y. Blood Cells Mol Dis 2003; 31: 102–11.CrossRefGoogle ScholarPubMed
Barton, JC, Wiener, HW, Acton, RT, Go, RC. Total blood lymphocyte counts in hemochromatosis probands with HFE C282Y homozygosity: relationship to severity of iron overload and HLA-A and -B alleles and haplotypes. BMC Blood Disord 2005; 5: 5.Google Scholar
Davis, WD, Arrowsmith, WR. The effect of repeated phlebotomies in hemochromatosis; report of three cases. J Lab Clin Med 1952; 39: 526–32.Google ScholarPubMed
Niederau, C, Fischer, R, Sonnenberg, A, Stremmel, W, Trampisch, HJ, Strohmeyer, G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985; 313: 1256–62.CrossRefGoogle ScholarPubMed
Niederau, C, Fischer, R, Purschel, A, Stremmel, W, Haussinger, D, Strohmeyer, G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 1107–19.CrossRefGoogle ScholarPubMed
Sephton-Smith, R. Iron excretion in thalassemia major after administration of chelating agents. Br Med J 1962; 2: 1577.CrossRefGoogle Scholar
Brittenham, GM, Griffith, PM, Nienhuis, AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567–73.CrossRefGoogle ScholarPubMed
Kontoghiorghes, GJ, Aldouri, MA, Sheppard, L, Hoffbrand, AV.1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1987; 1: 1294–5.CrossRefGoogle ScholarPubMed
Galanello, R, Piga, A, Alberti, D, Rouan, MC, Bigler, H, Sechaud, R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003; 43: 565–72.CrossRefGoogle ScholarPubMed
Simon, M, Pawlotsky, Y, Bourel, M, Fauchet, R, Genetet, B. Hémochromatose idiopathique: maladie associée a l'antigéne tissulaire HLA 3?Nouv Presse Méd 1975; 19: 1432.Google Scholar
Edwards, CQ, Griffen, LM, Goldgar, D, Drummond, C, Skolnick, MH, Kushner, JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318: 1355–62.CrossRefGoogle ScholarPubMed
Feder, JN, Gnirke, A, Thomas, W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399–408.CrossRefGoogle ScholarPubMed
Andrews, NC. Forging a field: the golden age of iron biology. Blood 2008; 112: 219–30.CrossRefGoogle ScholarPubMed
Phatak, PD, Sham, RL, Raubertas, RF, et al. Prevalence of hereditary hemochromatosis in 16031 primary care patients. Ann Intern Med 1998; 129: 954–61.CrossRefGoogle ScholarPubMed
Beutler, E, Felitti, V, Gelbart, T, Ho, N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 2000; 133: 329–37.CrossRefGoogle ScholarPubMed
Beutler, E, Felitti, VJ. The C282Y mutation does not shorten life span. Arch Intern Med 2002; 162: 1196–7.CrossRefGoogle Scholar
Asberg, A, Hveem, K, Thorstensen, K, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65 238 persons. Scand J Gastroenterol 2001; 36: 1108–15.Google Scholar
Olynyk, JK, Cullen, DJ, Aquilia, S, Rossi, E, Summerville, L, Powell, LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341: 718–24.CrossRefGoogle ScholarPubMed
Adams, PC, Reboussin, DM, Barton, JC, et al. Hemochromatosis and iron overload screening in a racially diverse population. N Engl J Med 2005; 352: 1769–78.CrossRefGoogle Scholar
Whitlock, EP, Garlitz, BA, Harris, EL, Beil, TL, Smith, PR. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2006; 145: 209–23.CrossRefGoogle ScholarPubMed
Screening for hemochromatosis: recommendation statement. Ann Intern Med 2006; 145: 204–8.
Barton, JC, Rothenberg, BE, Bertoli, LF, Acton, RT. Diagnosis of hemochromatosis in family members of probands: a comparison of phenotyping and HFE genotyping. Genet Med 1999; 1: 89–93.CrossRefGoogle ScholarPubMed
Acton, RT, Barton, JC, Passmore, LV, et al. Accuracy of family history of hemochromatosis or iron overload: the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol 2008.CrossRefGoogle ScholarPubMed
Barton, JC, Acton, RT. Population screening for hemochromatosis: has the time finally come?Curr Gastroenterol Rep 2000; 2: 18–26.CrossRefGoogle ScholarPubMed
Bacon, BR, Olynyk, JK, Brunt, EM, Britton, RS, Wolff, RK. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 1999; 130: 953–62.CrossRefGoogle ScholarPubMed
Waalen, J, Felitti, VJ, Gelbart, T, Beutler, E. Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood 2008; 111: 3373–6.CrossRefGoogle ScholarPubMed
Shaheen, NJ, Lawrence, LB, Bacon, BR, et al. Insurance, employment, and psychosocial consequences of a diagnosis of hereditary hemochromatosis in subjects without end organ damage. Am J Gastroenterol 2003; 98: 1175–80.CrossRefGoogle ScholarPubMed
Hicken, BL, Calhoun, DA, Barton, JC, Tucker, DC. Attitudes about and psychosocial outcomes of HFE genotyping for hemochromatosis. Genet Test 2004; 8: 90–7.CrossRefGoogle ScholarPubMed
Power, TE, Adams, PC, Barton, JC, et al. Psychosocial impact of genetic testing for hemochromatosis in the HEIRS Study: a comparison of participants recruited in Canada and in the United States. Genet Test 2007; 11: 55–64.CrossRefGoogle ScholarPubMed
Hall, MA, Barton, JC, Adams, PC, et al. Genetic screening for iron overload: No evidence of discrimination at 1 year. J Fam Pract 2007; 56: 829–34.Google ScholarPubMed
Barton, JC, Grindon, AJ, Barton, NH, Bertoli, LF. Hemochromatosis probands as blood donors. Transfusion 1999; 39: 578–85.CrossRefGoogle ScholarPubMed
Brittenham, GM, Klein, HG, Kushner, JP, Ajioka, RS. Preserving the national blood supply. Hematology Am Soc Hematol Educ Program 2001; 422–32.Google ScholarPubMed
Power, TE, Adams, PC. Hemochromatosis patients as voluntary blood donors. Can J Gastroenterol 2004; 18: 393–6.CrossRefGoogle ScholarPubMed
Camaschella, C, Roetto, A, Cali, A, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000; 25: 14–15.CrossRefGoogle Scholar
Merryweather-Clarke, AT, Cadet, E, Bomford, A, et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet 2003; 12: 2241–7.CrossRefGoogle ScholarPubMed
Roetto, A, Papanikolaou, G, Politou, M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003; 33: 21–2.CrossRefGoogle ScholarPubMed
Papanikolaou, G, Samuels, ME, Ludwig, EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004; 36: 77–82.CrossRefGoogle ScholarPubMed
Sham, RL, Phatak, PD, West, C, Lee, P, Andrews, C, Beutler, E. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood Cells Mol Dis 2005; 34: 157–61.CrossRefGoogle ScholarPubMed
Cooley, TB. A severe type of hereditary anemia with elliptocytosis: interesting sequence of splenectomy. Am J Med Sci 1945; 209: 561–8.CrossRefGoogle Scholar
Cotter, PD, Rucknagel, DL, Bishop, DF. X-linked sideroblastic anemia: identification of the mutation in the erythroid-specific delta-aminolevulinate synthase gene (ALAS2) in the original family described by Cooley. Blood 1994; 84: 3915–24.Google ScholarPubMed
Heilmeyer, L, Keller, W, Vivell, O, et al. [Congenital atransferrinemia in a 7-year-old girl.]Dtsch Med Wochenschr 1961; 86: 1745–51.CrossRefGoogle Scholar
Beutler, E, Gelbart, T, Lee, P, Trevino, R, Fernandez, MA, Fairbanks, VF. Molecular characterization of a case of atransferrinemia. Blood 2000; 96: 4071–4.Google ScholarPubMed
Miyajima, H, Nishimura, Y, Mizoguchi, K, Sakamoto, M, Shimizu, T, Honda, N. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 1987; 37: 761–7.CrossRefGoogle ScholarPubMed
Harris, ZL, Takahashi, Y, Miyajima, H, Serizawa, M, MacGillivray, RT, Gitlin, JD. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci USA 1995; 92: 2539–43.CrossRefGoogle ScholarPubMed
Yoshida, K, Furihata, K, Takeda, S, et al. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat Genet 1995; 9: 267–72.CrossRefGoogle ScholarPubMed
Beaumont, C, Leneuve, P, Devaux, I, et al. Mutation in the iron responsive element of the L ferritin mRNA in a family with dominant hyperferritinaemia and cataract. Nat Genet 1995; 11: 444–6.CrossRefGoogle Scholar
Girelli, D, Corrocher, R, Bisceglia, L, et al. Molecular basis for the recently described hereditary hyperferritinemia-cataract syndrome: a mutation in the iron-responsive element of ferritin L-subunit gene (the “Verona mutation”). Blood 1995; 86: 4050–3.Google Scholar
Girelli, D, Olivieri, O, Franceschi, L, Corrocher, R, Bergamaschi, G, Cazzola, M. A linkage between hereditary hyperferritinaemia not related to iron overload and autosomal dominant congenital cataract. Br J Haematol 1995; 90: 931–4.CrossRefGoogle Scholar
Pietrangelo, A, Montosi, G, Totaro, A, et al. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. N Engl J Med 1999; 341: 725–32.CrossRefGoogle ScholarPubMed
Montosi, G, Donovan, A, Totaro, A, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001; 108: 619–23.CrossRefGoogle ScholarPubMed
Kato, J.[Mutation of H-ferritin gene in a family associated with hereditary iron overload: a new iron overload-related gene?]Rinsho Ketsueki 2001; 42: 403–7.CrossRefGoogle Scholar
Priwitzerova, M, Pospisilova, D, Prchal, JT, et al. Severe hypochromic microcytic anemia caused by a congenital defect of the iron transport pathway in erythroid cells. Blood 2004; 103: 3991–2.CrossRefGoogle ScholarPubMed
Mims, MP, Guan, Y, Pospisilova, D, et al. Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood 2005; 105: 1337–42.CrossRefGoogle Scholar
Camaschella, C, Campanella, A, Falco, L, et al. The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood 2007; 110: 1353–8.CrossRefGoogle ScholarPubMed
Gordeuk, V, Mukiibi, J, Hasstedt, SJ, et al. Iron overload in Africa. Interaction between a gene and dietary iron content. N Engl J Med 1992; 326: 95–100.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×